TRT and 'hormone optimization': separating real benefits from biohacker hype

What's this video probably claiming?

Given the hashtag stack here, @alex.optimize is almost certainly running through some version of the testosterone optimization pitch that dominates biohacking TikTok. That usually means: low testosterone is making you tired, fat, and mentally foggy; TRT is the fix; and doctors are either too cautious or too ignorant to prescribe it aggressively enough. The antiaging angle is a reliable tell. Creators in this space frequently conflate hypogonadism, which is a diagnosable medical condition, with the normal age-related testosterone decline that starts around age 30 and drops roughly 1-2% per year. Those are genuinely different clinical situations. The video probably also gestures at "optimal" testosterone ranges that sit well above standard clinical reference ranges, which is where things get medically murky fast.

There may also be claims about testosterone's effects on muscle, cognition, libido, and cardiovascular health, each of which has a real evidence base and a dramatically overstated social media version running in parallel.

What does the science actually show?

TRT has solid evidence for men with confirmed hypogonadism, generally defined as total testosterone below 300 ng/dL combined with symptomatic presentation. The Testosterone Trials, a coordinated set of seven placebo-controlled studies published in the New England Journal of Medicine and affiliated journals between 2016 and 2017, found meaningful improvements in sexual function, bone density, and anemia in men aged 65 and older with low testosterone. Mood and energy improvements were more modest. Cognitive benefits were essentially nil in that population.

For muscle and body composition, a landmark study by Bhasin et al. (1996, NEJM) showed dose-dependent increases in lean mass and strength, but subjects received supraphysiologic doses of 600 mg testosterone enanthate weekly, far above therapeutic ranges. Extrapolating that to standard TRT doses of 100-200 mg weekly is a stretch the data does not support cleanly. Libido improvements are probably the most consistently replicated benefit across studies, even at physiologic replacement doses.

Where does the social media noise diverge from clinical reality?

The biggest divergence is the "optimization" framing. Clinical TRT is designed to restore testosterone to a normal physiologic range, not to push it to the top of that range or beyond. When creators talk about targeting 900-1100 ng/dL as a goal, they are describing something closer to performance enhancement than medical treatment, even if the doses involved are technically prescribed.

Cardiovascular risk is also routinely minimized in biohacking content. The TRAVERSE trial (Lincoff et al., 2023, NEJM), a large randomized cardiovascular safety trial of about 5,200 men, found TRT was non-inferior to placebo for major cardiac events, which is genuinely reassuring. But it also found significantly higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group. That nuance rarely makes it into the 60-second pitch. Erythrocytosis, an increase in red blood cell mass that raises clotting risk, affects a meaningful percentage of TRT users and requires monitoring. Creators almost never mention hematocrit checks.

What should you actually know?

If you are watching this video and wondering whether TRT is right for you, the actual clinical answer starts with blood work, not content. A single morning total testosterone measurement is not sufficient for diagnosis. Guidelines from the Endocrine Society recommend at least two measurements on separate days, along with luteinizing hormone and follicle-stimulating hormone levels to understand whether low testosterone is primary or secondary. Free testosterone matters too, especially in men with obesity or elevated sex hormone-binding globulin.

TRT is also not reversible in a casual sense. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, often significantly reducing endogenous production and testicular volume. Fertility can be substantially impaired. Stopping after extended use typically requires a structured protocol to recover natural production, and recovery is not guaranteed in all cases. These are real trade-offs that deserve weight in any honest conversation about hormone therapy, and they are largely absent from the biohacking content ecosystem.